Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in InventoryChange in InventoryChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InflaRx (IFRX) Net Cash Flow (2016 - 2026)

InflaRx's Net Cash Flow history spans 9 years, with the latest figure at -$1.6 million for Q1 2026.

  • On a quarterly basis, Net Cash Flow fell 104.82% to -$1.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$34.8 million, a 244.42% decrease, with the full-year FY2025 number at $1.4 million, down 67.91% from a year prior.
  • Net Cash Flow hit -$1.6 million in Q1 2026 for InflaRx, down from $11.3 million in the prior quarter.
  • Over the last five years, Net Cash Flow for IFRX hit a ceiling of $32.2 million in Q1 2025 and a floor of -$36.9 million in Q2 2025.
  • Historically, Net Cash Flow has averaged $44772.5 across 5 years, with a median of -$1.2 million in 2022.
  • Biggest five-year swings in Net Cash Flow: crashed 616.19% in 2023 and later skyrocketed 284.35% in 2024.
  • Tracing IFRX's Net Cash Flow over 5 years: stood at -$1.2 million in 2022, then crashed by 616.19% to -$8.8 million in 2023, then dropped by 12.95% to -$9.9 million in 2024, then soared by 213.69% to $11.3 million in 2025, then plummeted by 113.82% to -$1.6 million in 2026.
  • Business Quant data shows Net Cash Flow for IFRX at -$1.6 million in Q1 2026, $11.3 million in Q4 2025, and -$7.6 million in Q3 2025.